December 11, 2017
…to fight infections and cancer. They uncovered a novel function for a protein known as “Runx3” that is key to the development of killer T cells—immune cells important for fighting infections and cancer. The researchers believe Runx3, if properly directed, could be combined with other approaches to help T cells…
September 21, 2020
Moores Cancer Center at UC San Diego Health is using advanced imaging, genomics, personalized medicine and new therapies to treat patients like Brian McCloskey, who has stage IV prostate cancer.
January 19, 2023
UC San Diego researchers describe how pancreatic cancer stem cells leverage a protein in a family of proteins that normally suppress tumors to instead do the opposite, boosting their resistance to conventional treatments and spurring growth.
November 1, 2016
Researchers at University of California San Diego School of Medicine and Mayo Clinic provide the first evidence that the Hedgehog signaling pathway is central to the formation of gastrointestinal stromal tumors (GIST), which are frequently driven by the KIT oncogene.
November 14, 2017
Primary liver cancer is now the second leading cause of cancer-related death worldwide, and its incidences and mortality are increasing rapidly in the United Stated. In late stages of the malignancy, there are no effective treatments or drugs. However, an unexpected finding made by a team of University of California…
March 11, 2020
From a simple blood draw, microbial DNA may reveal who has cancer and which type, even at early stages.
October 12, 2018
…stage IV pancreatic neuroendocrine cancer for more than three years. Current treatments, although effective for her, are highly toxic. Tamara enrolled in a first-of-its-kind, pilot study at Moores Cancer Center at UC San Diego Health to test a personalized vaccine using her unique cancer mutations to boost an anti-tumor immune…
July 27, 2015
…event will support research and patient care at Moores Cancer Center at UC San Diego Health.
August 15, 2017
Using fragments of circulating tumor DNA in blood, University of California San Diego School of Medicine researchers were able to identify theoretically targetable genetic alterations in 66 percent of patients with cancer of unknown primary (CUP), a rare disease with seven to 12 cases per 100,000 people each year.
May 4, 2016
Researchers at University of California San Diego School of Medicine have shown that ozanimod (RPC1063), a novel drug molecule, is moderately effective in the treatment of ulcerative colitis. Results of the Phase II clinical trial will appear in the May 5 issue of the New England Journal of Medicine.
